Blog

Corrects presentation date and spelling error

INDIANAPOLIS, INDIANA / ACCESS Newswire / September 3, 2025 / The executive team of Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, is scheduled to present at the 2025 H.C. Wainwright Annual Conference Monday, September 8, 2025, at 9:30 – 10 a.m. EDT in New York City.

Presenting will be CEO Dan O’Toole, Chief Strategy Officer Neerav Shah, Chief Financial Officer Todd Pepmeier and Chief Operations Officer Mark Hamm.

The team will discuss how Arrive AI’s platform will revolutionize the package delivery industry for courier companies, retailers and consumers, as well as offering efficiencies to the healthcare industry, specifically for hospitals and pharmaceutical deliveries.

-30-

About Arrive AI

Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and via the company’s press kit.

Media contact: Cheryl Reed, media@arriveai.com

Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s SEC reports for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 3, 2025 / Market inflection points are often hard to recognize until they’ve already revealed the winners. Carbon credits in the early 2000s. ESG reporting systems in the 2010s. Each began as a niche concept, often dismissed as a policy experiment or compliance burden. But once governments codified them into regulation, the companies at the forefront didn’t just grow; they defined categories, captured billions in enterprise value, and rewrote the playbook for sustainability-linked markets.

That’s why Singapore’s launch of the world’s first national plastic passport program, built with SMX (NASDAQ:SMX) and its national research agency ASTAR, is so significant. This is not a pledge or a pilot. It is government-backed infrastructure. By embedding SMX’s molecular-level traceability technology directly into Singapore’s plastics framework, the country has signaled that recycling will no longer be based on voluntary reporting or fragmented pilots. It will be governed by proof, verified at the material level, and enforced at the policy level.

For SMX, the opportunity is immense. It’s the equivalent of a defense contractor winning a sovereign contract in a sector worth billions. The difference is that plastic recycling is not confined to one nation’s defense budget; it’s a multi-billion-dollar global market with no functioning backbone until now. Singapore just delivered that backbone, and SMX is the company carrying it.

Parallels to Carbon Credits and ESG Compliance Tech

The path from niche innovation to mainstream adoption in sustainability has clear precedents. When carbon credits first emerged, skeptics dismissed them as abstract accounting tricks. Yet once compliance frameworks were built, markets materialized, capital flowed, and the companies enabling verification and trading became indispensable. The same pattern played out with ESG compliance technology. At first, companies cobbled together spreadsheets and consultants. Then governments, investors, and regulators demanded real-time, auditable reporting- and the platforms that could deliver it created enduring shareholder value.

SMX is now positioned at the same tipping point. Its patented molecular markers are embedded directly into plastics, metals, textiles, and natural rubber, giving every item a scannable, tamper-resistant identity tied to a verified digital passport. That data follows goods from origin through use, recycling, and chemical transformation, proving recycled content, authenticity, and chain of custody in real time. The result is enforceable compliance, anti-counterfeiting, and true material efficiency that converts sustainability from promise to measurable value.

Singapore’s plastic passport program showcases this power in practice. With SMX embedded at the national level, the country can ensure that every plastic product, from industrial resins to consumer packaging, carries a traceable, verifiable lifecycle. That’s not just policy; it’s monetization. Just as carbon credits turned emissions reductions into financial assets, SMX’s system transforms plastics into investable resources. And with the Plastic Cycle Token (PCT) framework layered on top, verified recycled inputs can now be priced, traded, and financed as standardized assets.

Inflection Point for Investors

Inflection points are defined not when technologies are proven, but when policy catches up and enforces them. Singapore has done precisely that, turning plastic recycling into national infrastructure rather than voluntary compliance. With 957,000 tonnes of annual plastic waste and a high reliance on incineration, the country has a real incentive to make this work.

But the bigger picture is regional and global. ASEAN has already outlined plastics sustainability as a core policy priority, while Europe is building digital product passport frameworks across materials. Singapore’s model, powered by SMX technology, provides the first working template that others can adapt.

For stakeholders, that signals leverage far beyond one contract. It means SMX now owns the reference architecture for national plastics programs. Singapore is the proof-of-concept. The prize is replication across dozens of other markets with similar mandates.

Consider how this played out in carbon. The first registries and verification platforms didn’t just win one geography; they scaled globally, cementing themselves as standards. Their market caps grew not linearly but exponentially, because they sat at the center of a new compliance-driven economy. SMX’s role in plastics recycling points to the same trajectory.

SMX Is The Architect Of A New Market

SMX now occupies rare territory: both a technology enabler and a market architect. It has proven capability at the molecular level, and it now has government validation at the national level. That is the recipe for an inflection point; where a story shifts from possibility to inevitability, and from early adopter risk to broad market upside.

Singapore may be the first chapter, but for SMX, it represents only the beginning. The plastics market is vast, fragmented, and desperate for a solution that unites environmental ambition with financial incentive. SMX has shown it can deliver that solution. Those who recognize the parallel to past sustainability markets will see this moment for what it is: a structural shift; the kind that redefines not only a company’s trajectory but a country’s path to proving that plastics can be managed as assets, not liabilities.

References

• https://www.fortunebusinessinsights.com/recycled-plastic-market-102568#:~:text=The%20global%20recycled%20plastics%20market,share%20of%2060.55%25%20in%202023.

• https://australiainstitute.org.au/post/carbon-credits-and-offsets-explained/

• National Environment Agency (NEA). Waste & Recycling Statistics 2014 – 2023. Singapore: NEA; 2024.

• Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.

• National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.

• National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.

• Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.

• National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.

• Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.

• Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.

• Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.

• National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / September 3, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”), retracts in its entirety, at the request of CIRO, the press release that was disseminated on September 2, 2025. CoTec also confirms that it did not pay for the research report.

About CoTec

CoTec Holdings Corp. (TSX-V:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains for the United States and its allies.

CoTec’s mission is clear: accelerate the energy transition while strengthening U.S. economic and national security. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.

From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.

For more information, please visit www.cotec.ca

For further information, please contact:

Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement

Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the Report and management’s expectations with respect to its current and potential future investments and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social and transport disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR profile at www.sedar.com. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

SALT LAKE CITY, UT / ACCESS Newswire / September 3, 2025 / FatPipe, Inc. (NASDAQ:FATN) (“FatPipe” or the “Company”), a pioneer in enterprise-class, application-aware, secure software-defined wide area network (“SD-WAN”) solutions that provide the highest levels of reliability, security, and optimization for Wide Area Networks (WANs), today announced that FatPipe CEO Dr. Ragula Bhaskar will present to institutional investors and stock analysts at the H.C. Wainwright 27^th Annual Global Investment Conference in New York City on September 8-10, 2025.

The webcast presentation will be available starting at 7:00 a.m. EST on September 5, 2025, via the registration link and will remain accessible for a limited time following the event.

“We are excited to share FatPipe’s story with the global investment community at the H.C. Wainwright Conference,” said Dr. Ragula Bhaskar, CEO of FatPipe. “As a pioneer in SD-WAN with more than two decades of patented innovation, FatPipe continues to deliver mission-critical connectivity and security solutions to over 2,500 customers worldwide. With a proven, subscription-based model, strong profitability, and expansion into high-growth markets like SASE, cybersecurity, and network observability, we believe FatPipe is uniquely positioned to capture the multi-billion-dollar opportunities ahead of us. We look forward to discussing our growth strategy and the value we are creating for shareholders as we scale our global footprint.”

The conference is expected to have up to 2,000 attendees. According to Sagient Research Systems, investment bank H.C. Wainwright has been ranked the #1 Placement Agent in terms of the aggregate number of financings for growing public companies since 1998.

About FatPipe, Inc.

FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe’s SD-WAN, SASE / SIEM, Network Monitoring, and Cybersecurity products are sold by 200+ resellers worldwide. For more information, visit www.fatpipe.com. Follow us on X @FatPipe_Inc.

Forward-Looking Statements

Certain statements contained in this press release, including statements relating to the Company’s expectations regarding the completion, timing and size of its proposed public offering and listing may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on management’s current expectations and are inherently subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the offering and other risks described in FatPipe’s registration statement on Form S-1, as it may be amended from time to time. Except as required by law, FatPipe expressly disclaims a duty to provide updates to forward-looking statements, whether as a result of new information, future events or other occurrences.

Company Contact Info
Investor.ir@fatpipeinc.com

Investor Contact
Dave Gentry, CEO
RedChip Companies, Inc.
1.800.RED.CHIP (733-2447)
FATN@redchip.com

SOURCE: FatPipe Networks

View the original press release on ACCESS Newswire

Ambience’s seamless integration with Epic’s EHR improves patient experience, reduces burden for clinicians, and strengthens compliance for health system

SAN FRANCISCO, CA and YUMA, AZ / ACCESS Newswire / September 3, 2025 / Onvida Health and Ambience Healthcare today announced the launch of frontier ambient AI capabilities directly inside Epic’s Hyperspace and Haiku applications. This enterprise-wide deployment gives Onvida clinicians seamless access to Ambience’s chart summarization, ambient scribing, coding, and patient summary technology – all without ever leaving Epic.

Building on their successful partnership announced in May 2025, the integration enables Onvida clinicians to initiate visit recordings in Haiku using Ambience to generate comprehensive, coding-aware documentation across more than 200 specialties and subspecialties. This streamlined approach reduces documentation burden while maintaining the high-quality, compliant notes that Onvida’s clinical teams require across inpatient, outpatient, and emergency department settings.

“This deployment represents the perfect marriage of Epic’s trusted EHR and Ambience’s powerful AI. Our clinicians can now capture encounters seamlessly within their existing workflow while gaining access to the most advanced ambient documentation technology available,” said Marc Chasin, M.D., Senior Vice President and Chief Information Officer at Onvida Health.

Frontier AI Across All Settings of Care

Unlike single-feature tools, Ambience was built with a deep understanding of clinical workflows. Directly inside Epic, Onvida clinicians now have access to frontier AI capabilities before, during, and after patient encounters in English, Spanish, and other languages. Key features include:

Pre-visit

• Patient Recap – a chart summarization tool that analyzes the patient’s medical record and generates a comprehensive summary to help clinicians prepare for the visit

In-visit

• Ambient Scribing – the most powerful AI scribe in healthcare, capable of generating comprehensive, coding-aware documentation across 200 specialties and subspecialties, and informed by data from Ambience’s chart summarization tool, Patient Recap

• Patient Instructions – customized after-visit summaries for patients, their families, and caregivers, written to the patient’s level of medical knowledge

Post-visit

• Coding Assistant – a comprehensive coding tool that surfaces precise ICD-10 codes to clinicians based on the patient encounter

• HCC Compliance Validator – a compliance assistant that reviews documentation in real time to flag HCC-linked problems that lack MEAT support, helping clinicians correct issues before they impact compliance

“Health systems are not looking for another point solution. Each clinician needs an AI solution that has been purpose built for their workflow and specialty,” said Nikhil Buduma, Co-Founder and Chief Scientist of Ambience Healthcare.

“With this latest iteration of Ambience inside of Epic, we’ve delivered frontier capabilities that support clinicians before, during, and after the patient encounters.”

About Onvida Health

Onvida Health is a leading not-for-profit hospital system serving Yuma County and southwestern Arizona. The system includes two hospitals, 430 inpatient beds, 45 outpatient clinics and a free-standing Emergency Department. Onvida Health’s team includes 495 providers across 52 specialties, with 4,000 employees and hundreds of volunteers who work together to deliver high-quality, compassionate care. Together we are committed to delivering compassionate, patient-centered care in a welcoming and inclusive environment. At Onvida Health, our mission is clear: to build a healthier tomorrow for the communities we proudly serve.

About Ambience Healthcare

Ambience Healthcare is the leading AI platform for documentation, coding, and clinical workflow, built to reduce administrative burden and protect revenue integrity at the point of care. Trusted by top health systems across North America, Ambience’s platform is live across outpatient, emergency, and inpatient settings, supporting more than 100 specialties with real-time, coding-aware documentation. The platform integrates directly with Epic, Oracle Cerner, athenahealth, and other major EHRs. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco and backed by Oak HC/FT, Andreessen Horowitz (a16z), OpenAI Startup Fund, Kleiner Perkins, and other leading investors.

Media Contacts
Jenn Lotz Williams
Onvida Health
(504) 376-3253
jwilliams4@onvidahealth.org

Karina Stabile
Aria Marketing for Ambience Healthcare
kstabile@ariamarketing.com
516-317-5835

SOURCE: Ambience

View the original press release on ACCESS Newswire

INDIANAPOLIS, INDIANA / ACCESS Newswire / September 3, 2025 / The executive team of Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, is scheduled to present at the 2025 H.C. Wainwright Annual Conference Tuesday, September 9, 2025, at 9:30am – 10am EDT in New York City.

Presenting will be CEO Dan O’Tool, Chief Strategy Officer Neerav Shah, Chief Financial Officer Todd Pepmeier and Chief Operations Officer Mark Hamm.

The team will discuss how Arrive AI’s platform will revolutionize the package delivery industry for courier companies, retailers and consumers, as well as offering efficiencies to the healthcare industry, specifically for hospitals and pharmaceutical deliveries.

-30-

About Arrive AI

Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and via the company’s press kit.

Media contact: Cheryl Reed, media@arriveai.com

Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s SEC reports for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / September 3, 2025 / For decades, the world has struggled to balance the economics of plastic waste with the urgency of sustainability. Policymakers imposed targets, companies pledged billions, and NGOs kept up the pressure. Yet the frameworks were never designed to succeed. Recycling programs focused narrowly on bottles and packaging while ignoring the much larger streams of industrial resins, automotive polymers, textiles, and electronics. The result was predictable: recycling rates stalled, incineration rose, and the promise of sustainable plastics remained an aspiration.

That is where SMX (NASDAQ:SMX) steps in. Its technology delivers what the UN Plastics Treaty has long placed on its wish list-replacing systems that failed with a platform that works. By tracking all categories of plastics, not just PET bottles or rPET packaging, SMX broadens the scope of recycling into entirely new markets. Dashboards can be made from recycled automotive polymers, electronics casings reborn from industrial resins, and textiles repurposed instead of burned. In short, every neglected stockpile and undervalued waste stream becomes a revenue opportunity, turning what was once written off into measurable value across the supply chain.

This shift is now moving from concept to reality. SMX and Singapore’s research agency ASTAR announced its mission to power the world’s first national plastics passport program. This is more than a compliance tool. By embedding molecular markers directly into materials, every kilogram of recycled plastic can now be verified, audited, and transformed into a financial instrument: the Plastic Cycle Token, or PCT.

SMX Makes Plastic a Bankable Asset
With that, SMX delivers material efficiency in its purest form. The proof isn’t a label on the outside of a product; it’s built inside. SMX’s patented molecular markers are embedded directly into plastics, metals, textiles, and natural rubber, giving every item a scannable, tamper-resistant identity tied to a verified digital passport. That link follows goods from origin through use, recycling, and even chemical transformation, proving recycled content, authenticity, and chain of custody in real time. The result is enforceable compliance, anti-counterfeiting, and true material efficiency that converts sustainability from promise to measurable value.

Unlike carbon credits, which have long battled accusations of opacity and double counting, PCTs are rooted in a tangible, physical trail. Each token corresponds to a verified unit of recycled plastic, giving it both accountability and tradability. This turns waste management into asset management. Recyclers can monetize output, brands can hedge their compliance exposure, and investors gain access to a new class of commodities tied directly to resource efficiency.

In a country like Singapore, the numbers are compelling. Redirecting just a third of today’s plastic waste into an SMX-verified loop could generate more than S$100 million annually in avoided incineration costs and new recycled resin value. For governments, this is fiscal efficiency. For brands, it’s proof. For markets, it’s an entirely new way of pricing sustainability.

What makes this moment transformative is not the technology alone, but the economic blueprint it creates. Across ASEAN, demand for post-consumer resin is surging, with premiums of 5% to 15% over virgin polymer already common in regulated sectors like automotive and electronics. As extended producer responsibility schemes tighten, verified supply will be worth even more. SMX’s model shows how supply chains can evolve from fragmented reporting systems into fully auditable markets, where sustainability is no longer a cost center but a profit driver.

Singapore’s program is historic on its own, but replicated regionally, the model unlocks an addressable market worth about S$4.2 billion annually in certified recycled materials and platform fees. The shift is clear: what once looked like a regulatory headache is now becoming a lever for competitiveness and growth.

SMX’s Defining Inflection Point
For SMX, this marks a shift from promise to proof. Years of pilots and R&D have culminated in the first national deployment of its platform. Singapore marks just the beginning. If this model spreads across ASEAN, SMX is positioned not only as a technology enabler, but as the architect of an entirely new marketplace.

The lesson here is simple: sustainability efforts fail when treated only as obligations. They succeed when they unlock new value. By converting plastics from environmental liabilities into verified financial assets, SMX is changing the conversation. Waste is no longer waste. It’s a resource with a measurable price, a tradable proof point, and a role in the next generation of global supply chains.

References

1. National Environment Agency (NEA). Waste & Recycling Statistics 2014 – 2023. Singapore: NEA; 2024.

2. Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.

3. National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.

4. National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.

5. Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.

6. National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.

7. Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.

8. Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.

9. Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.

10. National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.

About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

• Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

• TxB2 is a biomarker indicating aspirin’s effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots

• This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage

• Lab results showed Aspire’s product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment

• These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, today announced positive final results from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The final results demonstrated that Aspire’s sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA, the active antiplatelet form of aspirin) compared to chewed aspirin tablets (p0.05), as detailed in Aspire’s previous press release. The product was also safe and well-tolerated by patients, and no adverse events were reported. However, even more clinically significant results were discovered since the press release announcing top-line results was issued on August 18, 2025.

Important New Findings

Aspire’s OTASA BA2039 sublingual formulation also significantly inhibited serum thromboxane B₂ (TxB₂) within the first two minutes after dosing compared to the chewed oral aspirin tablets (p0.02). TxB₂ is a biomarker for the effect of aspirin on platelet aggregation. This has significant and important positive implications for its role in the inhibition of blood clotting and its role in heart attacks.

These important results underscore the potential of Aspire’s sublingual aspirin product to be the market-leading treatment for suspected acute myocardial infarction (AMI, blockage of blood flow to heart muscle causing damage or death of heart tissue – commonly known as a “heart attack”). There are an estimated 18 million Americans living with coronary artery disease with approximately 800,000 per year experiencing an AMI leading to 300,000 deaths.

According to a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines dated April 1, 2025, “Aspirin has long been considered an integral part of anti-platelet therapy to prevent recurrent atherothrombotic events among patients with Acute Coronary Syndromes (ACS). Aspirin reduces the incidence of vascular death after AMI, and in secondary prevention trials (that include patients after MI), it re-duces the occurrence of vascular and coronary events, including MI and stroke.

Aspirin should be initiated with a loading dose (162-325 mg) in patients with ACS without an absolute contraindication as soon as possible on presentation irrespective of final management strategy (invasive or noninvasive).” Aspire’s sublingual product rapidly delivers 162.5 mg of aspirin, precisely in the range suggested by this study, and Aspire’s product begins to show TxB2 inhibition in two minutes or less.”

Kraig Higginson, Interim Chief Executive Officer of Aspire, commented, “The final results from our recent clinical trial confirm our belief that our high dose sublingual aspirin has to the potential to be a life-changing, market-leading treatment for patients experiencing a suspected heart attack. Patients in our study experienced a significantly improved time of inhibition of TxB₂, a biomarker for platelet aggregation, the process where activated platelets stick to each other to block the flow of blood to heart muscle. We believe our new sublingually delivered aspirin has the potential to save lives. We look forward to presenting these data to the FDA as we move down the development pathway towards potential commercialization of our safe, novel and effective sublingual form of high dose aspirin. We hope the day will soon come that every EMT, emergency service provider, and hospital will have our sublingual aspirin on hand for those suffering from heart attacks.”

* TxB₂ is a stable metabolite of thromboxane A₂ (TxA₂), a potent chemical that promotes platelet clumping and vasoconstriction. Measuring low levels of TxB₂ confirms that aspirin is working as intended.

The results of Aspire’s clinical study suggest that sublingual administration of aspirin provides earlier drug exposure and platelet inhibition than the current standard-of-care, which is chewing and swallowing uncoated aspirin tablets. Numerous published studies indicate that an even more rapid pharmacodynamic effect would be desirable during the early phase of thrombus evolution in the setting of myocardial infarction or ischemic stroke (i.e., the sooner TxB2 concentration can be reduced, the better for the patient). Reducing mean serum TxB₂ concentration after aspirin dosing-which the clinical study demonstrates that Aspire’s sublingual aspirin product does rapidly, starting in 2 minutes or less–indicates successful inhibition of platelet aggregation, which may reduce the risk of vascular death and other major adverse cardiovascular events.

Advancing Aspire’s Sublingual Aspirin

Aspire plans to review its clinical trial results with the U.S. Food and Drug Administration (FDA) to enable a potential regulatory submission for accelerated approval in the third quarter of 2025.

About Aspire’s Clinical trial AB-101

Clinical trial AB-101 was a randomized crossover bioavailability study of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets. Six otherwise healthy 40 to 65-year-old subjects were administered 162 mg aspirin as a single dose in each of three treatment periods separated by two 14-day washout periods. Two different investigational sublingual powder and granule formulations (Aspire Biopharma) and chewed uncoated oral aspirin tablets (Bayer) were studied. The primary objective of the clinical trial was to evaluate the bioavailability of ASA in plasma over eight hours after dosing. An additional objective was to evaluate the potentially life-saving effect of each treatment on serum TxB₂.

Aspire’s sublingual aspirin is an investigational new drug and has not been approved for marketing by FDA or any other government regulatory authority.

About Oral Aspirin

Oral aspirin is FDA-approved for treatment of suspected AMI with the initial dose of 160-162.5 mg is administered as soon as an AMI is suspected.ⁱ In a large, multicenter study of aspirin, streptokinase, and the combination of aspirin and streptokinase in 17,187 patients with suspected AMI, aspirin treatment produced a 23 percent reduction in the risk of death from cardiovascular diseases within five weeks.ⁱⁱ Clinical practice guidelines recommend that aspirin be initiated as soon as possible with the initial dose chewed, when possible, to achieve faster onset of antiplatelet action.ⁱⁱⁱ

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

View the original press release on ACCESS Newswire